• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of cancer-specific drug carriers possessing comprehensive inhibitory effect of ABC transporters

Research Project

Project/Area Number 18K06790
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionTohoku Medical and Pharmaceutical University

Principal Investigator

Morimoto Kaori  東北医科薬科大学, 薬学部, 講師 (90401009)

Co-Investigator(Kenkyū-buntansha) 荻原 琢男  高崎健康福祉大学, 薬学部, 教授 (80448886)
石井 敬  東北医科薬科大学, 薬学部, 講師 (00735714)
Project Period (FY) 2018-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywordsトランスポーター / デキストラン誘導体 / 薬物送達システム / 多剤耐性 / ABCトランスポーター / Dextran / transporter / デキストラン / EPR効果 / Drug delivery system / 多剤耐性克服 / DDS / がん多剤耐性克服 / ABC transporter
Outline of Final Research Achievements

We investigated whether dextran and its derivatives inhibit BCRP, MRP1, and P-gp in vitro. In Sf-9 membrane vesicles overexpressing BCRP, MRP1, and P-gp, BCRP and MRP1 were significantly inhibited by 2-hydroxypropyl-trimethylammonium-dextran of 4 kDa and 70 kDa (Q-D4 and Q-D70); however, P-gp was not inhibited. A structure-activity study showed that Q-D4, Q-D70, and 40 kDa diethylaminoethyl-dextran (DEAE-D40) significantly inhibited BCRP, while 4 kDa, 40 kDa, and 70 kDa dextrans, dextran sulfate, and the saccharide components of dextran did not. These results suggest that the cationic moieties are important for BCRP inhibition. However, cell-based efflux assay revealed that Q-D4, Q-D70, and DEAE-D40 did not increase the retention of fluorescent substrates in BCRP-, MRP1- and P-gp-overexpressing KB cells. The ineffectiveness in cellular systems is presumably due to inability of the dextran derivatives to access transporters located on the cytoplasmic side of the cell membrane.

Academic Significance and Societal Importance of the Research Achievements

本研究でカチオン修飾デキストランがBCRPとMRP1を阻害する能力を有するが、細胞レベルでは効果がないことを明らかにした。複数の薬物排出トランスポーターを同時に阻害するがん組織特異的ドラッグデリバリーシステムは、がん化学療法の有効性と安全性を高めるために有効である可能性があり、そのための基礎データとして有用な情報を得ることが出来たと考える。

Report

(5 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2021 2018

All Presentation (4 results)

  • [Presentation] Dextranによる多剤耐性関連輸送体の阻害効果2021

    • Author(s)
      森本かおり, 石井 敬, 杉本 芳一, 荻原 琢男, 富田 幹雄
    • Organizer
      日本薬学会第141年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Cationic modification gives dextran a BCRP inhibitory effect2021

    • Author(s)
      森本かおり, 石井 敬, 杉本 芳一, 荻原 琢男, 富田 幹雄
    • Organizer
      日本薬物動態学会第36回年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Dextranによる多剤耐性関連輸送体の阻害効果2021

    • Author(s)
      森本かおり、石井敬、杉本芳一、荻原琢男、富田幹雄
    • Organizer
      日本薬学会第141年会
    • Related Report
      2020 Research-status Report
  • [Presentation] Dextranによる複数のABC transporterの同時阻害2018

    • Author(s)
      石井敬、森本かおり、熊谷茉歩、富田幹雄
    • Organizer
      第57回日本薬学会東北支部会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi